Recent Posts
- Former valley doctor found negligent
- Lawsuit claims police brutality
- Settlement reached in lawsuit against physician
- Suit claims private guard failed to thwart Kirkwood council shooting
- British veteran joins W.Va. National Guard lawsuit
- Wrongful death lawsuit filed in fatal shooting by KC police
- Illinois Supreme Court strikes down medical malpractice law
- Former mine permits chief files ‘whistleblower’ suit
- Key phase of gene-patent lawsuit in judge’s hands
- Move to make H’field’s off-campus policy a federal case
- Suit says woman hit, hurt by bobsled in Park City
- Suit: Penthouse Club cocktail waitress Lourdes Garcia claims female boss, male bartender hit on her
- Lawsuit: Principal was speeding, ran red light
- Bank of America faces fraud lawsuit
- Fifth Third sued over overdraft policies
Archived Posts
- February 2010 (42)
- January 2010 (119)
- December 2009 (8)
- November 2009 (165)
- October 2009 (1)
- June 2009 (29)
- April 2009 (61)
- March 2009 (140)
- February 2009 (156)
- January 2009 (151)
- December 2008 (143)
- November 2008 (113)
- October 2008 (192)
- September 2008 (88)
- August 2008 (8)
- July 2008 (29)
Blogroll
Pages
Meta
Data From Studies of Pfizer Neurontin Drug May Have Been Skewed
November 13, 2009
Researchers say trials of Pfizer Inc.’s Neurontin epilepsy treatment for uses that were not yet approved may have been skewed to emphasize favorable results.
Comparisons of internal company documents with published data from 12 clinical trials found inconsistencies between data that made it into the medical journals and findings from the original trials, according to a report in tomorrow’s New England Journal of Medicine. Discrepancies included reports of positive results from trials that were initially found to be negative, and primary study goals reported as secondary study goals.
Pfizer paid $430 million in criminal fines and civil penalties in 2004 for urging doctors to prescribe Neurontin for off-label uses. The drugmaker said the new review isn’t credible and the company didn’t attempt to mislead the medical community.
Read Article: Bloomberg
Posted By: Arizona Phoenix Attorneys for Accidents on the Premises of Others
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL